OXOLIFE

Oxolife: Enhancing embryo implantation. Improving women’s fertility Oxolife is a small-size clinical-stage company focused on female fertility. We are developing an innovative treatment, OXO-001),to enhance female fertility success, improving embryo implantation trough a direct effect on the endometrium . A second research line focuses on restoring PCOS-related infertility (polycystic ovarian syndrome). OXO-001 is a first-in-class drug due to its mechanism of action, solving an unmet medical need as there is no solution drug available in the embryo implantation segment today. The phase II clinical trial with encouraging primary results, is anticipated to be completed by the end 2023. The company is preparing for the last stages of clinical development. Oxolife’s team is led by Agnès Arbat, Medical Doctor (Co-founder and CEO), and Ignasi Canals, Biochemist PhD (Co-founder and CSO). Oxolife’s team accumulates a broad experience in the Women’s health pharmaceutical industry and drug development. The team has continuous support from Clinical and Scientific Opinion Leaders from prestigious centers in fertility and R&D.